Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Re test of last years lows?
View:
Post by jeffm34 on Jan 26, 2021 11:51am

Re test of last years lows?

That's one ugly looking chart. All on the heels of amazing news.
Comment by scarlet1967 on Jan 26, 2021 12:16pm
All these amazing news have not been communicated to the market effectively. They have not done enough and in a correct manner to market the amazing news. For instance their posts on LinkedIn and Twitter has not generated any meaningful response or reaction. The put a couple of clips on their own YouTube platform  re Ibalizumab last year with less than 20 views(probably all company's ...more  
Comment by Bucknelly21 on Jan 26, 2021 1:06pm
This might be the the only team who could have this big of news and see their sp decline over and over. (Probably not the only one but pretty tough to do)
Comment by Adonis on Jan 26, 2021 1:11pm
Who sell at this price !?
Comment by Bucknelly21 on Jan 26, 2021 1:12pm
Can you imagine those new shareholders... probably feel so happy that they sold all the shares from the offering, Thtx you got played... again...
Comment by jeffm34 on Jan 26, 2021 1:28pm
It doesn't help when you ignore the bigger more important firms to do a sweetheart deal (at the time) with your friends you still have at NB.  There were rumours when they did their prior financing that they pissed off the wrong people back then too.  I guess they don't learn. I'm curious to see the next short report. I think someone is sending a clear message to management ...more  
Comment by scarlet1967 on Jan 26, 2021 1:39pm
The SP has been declining prior to the financing despite the HIV NASH(which is bigger market than HIV MDR) despite the preclinical sort1 news, despite new experience CEO, despite the announcement of the general NASH. Despite the good PR. I guess the only thing they have learned is so far they haven't learned from past failed marketing efforts.
Comment by BilliB7 on Jan 26, 2021 2:28pm
you have invested in Canada's most shady and corrupt province by a mile. from the Olympics to SNC Lavelin to Bombardier . and with Quebec Liberals running the country again always be wary
Comment by jeffm34 on Jan 26, 2021 2:39pm
I've often wondered how much that has hindered the company as well. It just looks bad when your CFO has previous connections with one of the recipients of this ridiculous deal.  If the company was serious about raising their profile they would have done this deal with a US firm along with moving the company to the US. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities